menu
    • menu
    [{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"NXC-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Agreement","leadProduct":"NXC-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Undisclosed"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Immix Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Immix Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Immix Biopharma"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"NXC-201","moa":"","graph1":"Genetic Disease","graph2":"Phase I","graph3":"Nexcella","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Nexcella \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Nexcella \/ Not Applicable"},{"orgOrder":0,"company":"Nexcella","sponsor":"CIRM","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"NXC-201","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Nexcella","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Nexcella \/ CIRM","highestDevelopmentStatusID":"14","companyTruncated":"Nexcella \/ CIRM"}]

    Find Clinical Drug Pipeline Developments & Deals by Nexcella

    Menu

    Nexcella

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : CIRM

                            Deal Size : $8.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            California Institute Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Trial

                            Details : The proceeds will support clinical development of company's chimeric antigen receptor T cell (CAR-T) therapy NXC-201 for the treatment of relapsed/refractory AL Amyloidosis.

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            July 25, 2024

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : CIRM

                            Deal Size : $8.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in US

                            Details : NXC-201 (formerly HBI0101) CAR-T involves autologous T cells transduced ex-vivo with anti-BCMA CAR retroviral vector, being evaluated for treating relapsed/refractory AL Amyloidosis.

                            Brand Name : HBI0101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            April 18, 2024

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing

                            Details : NXC-201 (formerly HBI0101) is an IND approved, BCMA-targeted investigational CAR-T cell therapy that is being studied in patients with relapsed/refractory AL amyloidosis.

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 21, 2023

                            Lead Product(s) : NXC-201,Cyclophosphamide,Fludarabine Phosphate

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration Approves Orphan Drug Designation for Nexcella NXC-201 as a Treatment for Amy...

                            Details : NXC-201, a next generation CAR-T cell therapy, is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of Amyloid Light Chain (AL) Amyloidosis and received orphan drug designation from FDA.

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 21, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Immix Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            U.S. Food and Drug Administration Approves Orphan Drug Designation for NXC-201 as a Treatment for Multiple Mye...

                            Details : NXC-201, a next generation CAR-T cell therapy, is currently being evaluated in a Phase 1b/2a clinical trial for the treatment of Multiple Myeloma and received orphan drug designation from FDA.

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            August 23, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Immix Biopharma

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nexcella Completes Pre-IND Meeting with FDA on NXC-201 US Clinical Trial

                            Details : NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myelom...

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 26, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nexcella Announces New Positive NXC-201 Clinical Data Demonstrating 100% Complete Responses in AL Amyloidosis ...

                            Details : NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myelom...

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            March 23, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nexcella Announces 50 Patients Already Treated with CAR-T NXC-201; Estimates 100-Patient Total Enrollment for ...

                            Details : NXC-201 (formerly HBI0101) is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myelom...

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 27, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Phase 1b/2 Clinical Trial to t...

                            Details : Nexcella, Inc. initiates process of bringing NXC-201 to the United States by entering into an agreement with a well-known GMP cell therapy manufacturer that will supply Phase 1b/2 NXC-201 clinical trial material.

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            February 15, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Nexcella

                            U.S.A arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Nexcella, Inc. Presents 42-Patient Interim Data, with 90% Overall Response Rate in Relapsed or Refractory Mult...

                            Details : NXC-201 is a BCMA-targeted investigational chimeric antigen receptor T (CAR-T) cell therapy that is being studied in a comprehensive clinical development program for the treatment of patients with relapsed or refractory multiple myeloma and AL amyloidosi...

                            Brand Name : NXC-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            February 09, 2023

                            Lead Product(s) : NXC-201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth